Pleotropic Effect of New Oral Anticoagulants

• Status: Unknown status
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Atrial fibrillation (AF) has been known to have several pathophysiologic mechanisms including endothelial dysfunction of heart and vessel. This study was designed to determine the efficacy of NOAC therapy in the prevention of endothelial dysfunction and progression of atherosclerosis of AF subjects.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kyunghee University Medical Center
• Treatments: Anticoagulants; Dabigatran; Warfarin

Criteria

Inclusion Criteria:

• CHA2DS2-VASc score above 2

Exclusion Criteria:

• severe peripheral arterial disease (greater than a Fontaine IIb category)

• grade 4 or higher cerebral infarction on the Modified Rankin Scale

• proven coronary artery disease by coronary angiogram

• severe hepatic or renal dysfunction

• uncontrolled congestive heart failure

• uncontrolled hypertension or diabetes mellitus

• hematologic disorders

• allergy or hypersensitivity to the investigational drugs

• pregnant or lactating women or women wishing to become pregnant